

PRINTER RUSH
(PTO ASSISTANCE)

Application : 09975776 Examiner : Lewis GAU : 1614
From: J. Blake Location: IDC FMF FDC Date: 9/12/05
Tracking #: DL1D8602 Week Date: 5123/05

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449		<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS		<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM		<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW		<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW		<input type="checkbox"/> Other
<input type="checkbox"/> DRW		
<input type="checkbox"/> OATH		
<input type="checkbox"/> 312		
<input type="checkbox"/> SPEC		

Attn Chief Draftsperson:

[RUSH] MESSAGE:

Drawings contain Shaded background.

Please review.

[XRUSH] RESPONSE:

Drawing objection mailed

INITIALS: *OBR*

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER 09/975,776	FILING/RECEIPT DATE 10/10/2001	FIRST NAMES APPLICANT ZHIWEI JIANG	ATTORNEY DOCKET NUMBER 22596-514 (CO-14)
---	--	--	--

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY
AND POPEO, P.C.
ONE FINANCIAL CENTER
BOSTON, MA 02111

Examiner
LEWIS, AMY A
Art Unit
1614
Paper Number

Date Mailed: 9/27/2005

Notice Regarding Drawings

Corrected drawings for the above-identified application, received in the USPTO on are still not acceptable for the reason(s) identified on the attached PTO-948. Applicant is given one opportunity to correct the informalities within a two-month time period from the mailing date of this Notice. **THIS TIME PERIOD IS NOT EXTENDABLE UNDER EITHER 37 CFR 1.136(a) OR 1.136(b).** Failure to take corrective action within the set period will result in abandonment of the application.

ATTACHMENT: PTO-948 Notice of Draftsperson's Patent Review
RETURN CORRECTED DRAWINGS TO:

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Clifton Randolph
Office of Patent Publication,
Publishing Division
703-305-0333 ext-128

09/975 776

NOTICE OF DRAFTSPERSON'S PATENT DRAWING REVIEW

The drawing(s) filed (insert date) 10/10/01 are:

- A. approved by the Draftsperson under 37 CFR 1.84 or 1.152.
 B. objected to by the Draftsperson under 37 CFR 1.84 or 1.152 for the reasons indicated below. Corrected drawings are required.

1. DRAWINGS. 37 CFR 1.84(a): Acceptable categories of drawings: Black ink or Color (3 sets required).

Color drawings are not acceptable until petition is granted. Fig(s) _____

Pencil and non black ink not permitted. Fig(s) _____

2. PHOTOGRAPHS. 37 CFR 1.84(b)

One (1) full-tone set is required. Fig(s) _____

Photographs may not be mounted. 37 CFR 1.84(e)

Photographs must meet paper size requirements of 37 CFR 1.84(f). Fig(s) _____

Poor quality (half-tone). Fig(s) _____

3. TYPE OF PAPER. 37 CFR 1.84(e)

Paper not flexible, strong, white, and durable. Fig(s) _____

Erasures, alterations, overwritings, interlineations, folds, copy machine marks not accepted. Fig(s) _____

4. SIZE OF PAPER. 37 CFR 1.84(f): Acceptable sizes:

21.0 cm by 29.7 cm (DIN size A4) or

21.6 cm by 27.9 cm (8 1/2 x 11 inches)

All drawing sheets not the same size. Sheet(s) _____

Drawings sheets not an acceptable size. Fig(s) _____

5. MARGINS. 37 CFR 1.84(g): Acceptable margins:

Top 2.5 cm Left 2.5 cm Right 1.5 cm Bottom 1.0 cm

Margins not acceptable. Fig(s) _____

Top (T) _____ Left (L) _____

Right (R) _____ Bottom (B) _____

6. VIEWS. 37 CFR 1.84(h)

REMINDER: Specification may require revision to correspond to drawing changes, e.g., if Fig. 1 is changed to Fig. 1A, Fig 1B and Fig. 1C, etc., the specification, at the Brief Description of the Drawings, must likewise be changed.

Views not labeled separately or properly. Fig(s) _____

7. SECTIONAL VIEWS. 37 CFR 1.84(h)(3)

Sectional designation should be noted with Arabic or Roman numbers. Fig(s) _____

8. ARRANGEMENT OF VIEWS. 37 CFR 1.84(i)

Words do not appear on a horizontal, left-to-right fashion when page is either upright or turned so that the top becomes the right side, except for graphs. Fig(s) _____

9. SCALE. 37 CFR 1.84(k)

Scale not large enough to show mechanism without crowding when drawing is reduced in size to two-thirds in reproduction. Fig(s) _____

10. CHARACTER OF LINES, NUMBERS, & LETTERS. 37 CFR 1.84(l)

Lines, numbers & letters not uniformly thick and well defined, clean, durable, and black (poor line quality). Fig(s) 1, 2, 8, 9, 10A, 10B

11. SHADING. 37 CFR 1.84(m)

Solid black areas pale. Fig(s) _____

Solid black shading not permitted. Fig(s) 1, 2

12. NUMBERS, LETTERS, & REFERENCE CHARACTERS. 37 CFR 1.84(p)

Numbers and reference characters not plain and legible. Fig(s) _____

Figure legends are poor. Fig(s) _____

Numbers and reference characters not oriented in the same direction as the view. 37 CFR 1.84(p)(1) Fig(s) _____

English alphabet not used. 37 CFR 1.84(p)(2) Fig(s) _____

Numbers, letters and reference characters must be at least 32 cm (1/8 inch) in height. 37 CFR 1.84(p)(3). Fig(s) _____

13. LEAD LINES. 37 CFR 1.84(q)

Lead lines missing. Fig(s) _____

14. NUMBERING OF SHEETS OF DRAWINGS.

37 CFR 1.84(t)

Sheets not numbered consecutively, and in Arabic numbers beginning with number 1. Sheet(s) _____

15. NUMBERING OF VIEWS. 37 CFR 1.84(u)

Views not numbered consecutively, and in Arabic numerals, beginning with number 1. Fig(s) _____

16. DESIGN DRAWINGS. 37 CFR 1.152

Surface shading shown not appropriate. Fig(s) _____

Solid black surface shading is not permitted except when used to represent the color black as well as color contrast. Fig(s) _____

COMMENTS:

Reviewer CBR

If you have questions, call (703) 305-8404.

Date 9/27/05
Attachment to Paper No. _____

beta-Lapachone Solubility




FIG. 1




FIG. 2




FIG. 3

Cell Line	Tissue Origins	Applied drug conc., μM		Colonies, percentage of control		
		β -Lapachone	Taxol	β -Lapachone	Taxol	β Lapachone + Taxol
A2780DDP	Ovary	2	0.2	77 (1.1)	39 (0.8)	0
MCF-7	Breast	4	0.1	46 (1.4)	45 (0.3)	0
21MT	Breast	4	0.1	56 (5.0)	63 (7.0)	0
Skmel-28	Melanoma	4	0.1	56 (1.4)	44 (5.1)	0
HT-29	Colon	4	0.1	42 (1.4)	64 (2.5)	0
ASPC-1	Pancreas	4	0.2	45 (1.9)	71 (0.8)	0
G480	Lung	4	0.2	32 (0.3)	39 (2.6)	2 (0.1)
DU145	Prostate	4	0.2	50 (2.2)	30 (0.9)	0

FIG. 4

β -Lap/Taxol Ratio, $\% IC_{50}$	OVCAR 3 Cell Line		MDA-H 2774 Cell Line	
	% Absorbance	Significance	% Absorbance	Significance
0/0	100		100	
100/0	61.2		51.2	
75/25	57.6	$p < 0.05$	30.5	$p < 0.05$
60/40	59.2		32.0	$p < 0.05$
50/50	54.9	$p < 0.05$	36.2	$p < 0.05$
40/60	54.3	$p < 0.05$	35.6	$p < 0.05$
25/75	55.8		39.2	$p < 0.05$
0/100	71.0		52.6	

FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10A

FIG. 10B